Ivonescimab Challenges Keytruda Beyond China

Ivonescimab has produced evidence to show superiority against pembrolizumab in advanced non-small-cell lung cancer.

The harder clinical-development question is whether a China-only trial can translate into a Western treatment setting built around different trial comparators, patient populations, and combination regimens.

Image

HARMONi-2 Changes The Evidence Base

At the September 2026 World Conference on Lung Cancer, investigators reported median overall survival of 30.8 months with ivonescimab versus 22.6 months with pembrolizumab. The stratified hazard ratio was 0.73, with a 95% confidence interval of 0.57 to 0.95 and P-value=0.009.

The result came from 398 patients with previously untreated, locally advanced or metastatic NSCLC. All had PD-L1-positive disease, defined as a tumour proportion score of at least 1%, and none had sensitising EGFR mutations or ALK translocations.

Patients received ivonescimab or pembrolizumab alone every three weeks.

This HARMONi-2 was a randomised, double-blind Phase III trial across 55 hospitals in China.

Its primary endpoint was progression-free survival. The earlier analysis reported 11.1 months versus 5.8 months, with a hazard ratio of 0.51.

Overall survival was a key secondary endpoint, and the latest analysis was prespecified rather than an exploratory post hoc comparison.

The survival results are very meaningful but has it sufficiently answered all the questions required for a ‘Western’ launch?

The safety profile also needs careful study.

Treatment-related adverse events of grade three or higher were reported in 29.9% of patients receiving ivonescimab and 21.6% receiving pembrolizumab.

Treatment-related events leading to discontinuation were uncommon in both groups, at 4.1% and 5.0%, respectively.

The latter safety endpoint is highly relevant because ivonescimab combines PD-1 blockade with VEGF inhibition in one bispecific antibody.

That bispecific mechanism creates a plausible efficacy advantage, but it also creates a different safety-management question from PD-1 inhibition alone.

A ‘Western’ development programme therefore needs to establish not only whether the survival signal translates, but whether the benefit-risk profile remains acceptable across the populations and treatment pathways in which the drug would actually be used.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

The Keytruda Comparison Is Complicated

Calling the result a simple win over Keytruda actually misses the more important clinical-development problem.

Pembrolizumab is not used in one uniform first-line NSCLC setting. Its pivotal evidence base includes different disease segments, PD-L1 thresholds, and treatment combinations.

KEYNOTE-024 established pembrolizumab monotherapy against platinum chemotherapy in patients with PD-L1 expression of at least 50%.

Additionally, KEYNOTE-042 extended the monotherapy comparison to patients with PD-L1 expression of at least 1%, although the trial enrolled patients internationally rather than exclusively in China.

The treatment landscape also moved towards combination therapy.

In combination therapy, KEYNOTE-189 demonstrated pembrolizumab plus pemetrexed and platinum chemotherapy improved overall and progression-free survival compared with chemotherapy alone in previously untreated metastatic non-squamous NSCLC.

KEYNOTE-407 similarly established pembrolizumab plus chemotherapy in metastatic squamous NSCLC.

This is the central translational issue here.

HARMONi-2 asked whether ivonescimab monotherapy can outperform pembrolizumab monotherapy in PD-L1-positive disease. That is the important question, and the answer is now strongly positive on the reported endpoints.

But a ‘Western’ team also needs to know whether ivonescimab can improve on the standard-of-care regimens clinicians already use when pembrolizumab is combined with chemotherapy.

That is why HARMONi-3 matters for the broader first-line market.

This global Phase III trial compares ivonescimab plus chemotherapy directly with pembrolizumab plus chemotherapy in first-line metastatic NSCLC, irrespective of PD-L1 expression. Its squamous and non-squamous cohorts are separately powered.

This standard-of-care question is not simply whether ivonescimab can replace Keytruda but whether the PD-1/VEGF combination can improve a treatment regime in which Keytruda is embedded.

Image

China-only Evidence Has Real Strengths and Limitations

The Chinese origin of HARMONi-2 is neither a reason to dismiss the findings nor proof that identical results will occur in Europe or North America.

The trial was large enough and rigorously designed to establish a randomised comparison.

Its double-blind structure, prespecified endpoints, independent assessment of tumour response, and mature survival follow-up all add weight.

The survival analysis also showed numerical benefit across prespecified clinical subgroups.

Yet subgroup numbers become much smaller when the 398-patient population is divided by PD-L1 expression, histology, age, and other characteristics.

The latest reported hazard ratio was 0.58 in patients with PD-L1 of at least 50%, compared with 0.85 in those with PD-L1 of 1% to 49%, with no statistical significance.

These analyses were descriptive and were not powered to establish subgroup efficacy.

The same issue appears by histology. The reported hazard ratio was 0.65 for squamous disease and 0.79 for non-squamous disease, with no statistical significance. These findings are signals for further study, not instructions for a new label.

The more useful comparison is therefore geographic replication through global development.

HARMONi, the first multinational Phase III study, enrolled patients across Asia, Europe, and North America in a different clinical setting: EGFR-mutated non-squamous NSCLC after progression on a third-generation EGFR tyrosine kinase inhibitor.

Ivonescimab was added to chemotherapy and compared with placebo plus chemotherapy.

The June 2026 update reported an overall survival hazard ratio of 0.76 in the global population.

The ‘Western’ subgroup also had a hazard ratio of 0.76, with 95% confidence interval of 0.52 to 1.10.

Median overall survival in Western patients was 17.5 months with ivonescimab plus chemotherapy and 14.0 months with chemotherapy alone.

That does not make HARMONi equivalent to HARMONi-2. The disease setting, treatment backbone, comparator, and statistical context are different. It does, however, provide an important piece of evidence that the molecule’s clinical effect is not confined to a China-only dataset.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

The Development Programme Is the Real Test

For ‘Western’ clinical development, the most important question is becoming one of positioning rather than proof of concept.

Ivonescimab is being tested in several configurations. HARMONi-3 addresses first-line NSCLC with chemotherapy and HARMONi-7 tests monotherapy against pembrolizumab in patients with high PD-L1 expression.

The HARMONi programme addresses post-TKI EGFR-mutated disease. Other Phase III studies are extending development into colorectal, urothelial, biliary tract, head and neck, and other solid tumours.

That breadth creates an opportunity, but it also raises a portfolio decision.

A drug can have a compelling mechanism and a statistically significant trial result without having one obvious commercial role.

For a ‘Western’ sponsor, the development plan needs to establish where ivonescimab creates incremental value against the regimen that patients would otherwise receive, not simply against the molecule that provides the most recognisable benchmark.

Three questions now deserve particular attention:

• Comparator relevance: Does ivonescimab outperform the current ‘Western’ standard in the exact treatment setting, rather than a historical or narrower comparator?
• Population transferability: Do efficacy and safety remain consistent across geography, ethnicity, disease biology, and treatment history?
• Positioning: Is the strongest role monotherapy, combination therapy, post-TKI treatment, or a broader tumour-type strategy?

A positive answer in one setting does not automatically establish the others.

The regulatory path also illustrates that distinction.

Summit’s U.S. Biologics Licence Application for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after third-generation TKI treatment is based on HARMONi, not HARMONi-2, with an FDA action date set for 14 November 2026.

Meanwhile, HARMONi-3 and HARMONi-7 address the first-line settings in which the HARMONi-2 data could have the greatest strategic relevance.

Image

What the HARMONi-2 Result Means for Global Development

HARMONi-2 has increased the level of confidence around ivonescimab.

The eight-month difference in median overall survival is clinically important. 

But the evidence must be read alongside the trial’s geography, monotherapy design, PD-L1 eligibility, comparator, and safety profile.

For Clinical Development leaders, the next trials are therefore more important.

The decisive evidence will come from trials designed around Western treatment practice.

HARMONi-3 can test whether ivonescimab improves on pembrolizumab plus chemotherapy, while HARMONi-7 can test whether the monotherapy signal holds in high PD-L1 disease.

The multinational HARMONi results already provide a separate indication that geographic transferability is plausible, while showing why confidence intervals and sample size matter when reading regional subgroups.

The broader lesson goes beyond one molecule. As more late-stage assets emerge from Chinese development programmes, global pharma teams will increasingly need to distinguish between evidence that travels through and evidence that still requires local confirmation.

The right response is neither automatic scepticism nor automatic extrapolation, but a sharper development question: What evidence would change the product’s role in the population where it must ultimately compete?

At Pharmatica, we track how clinical evidence moves from trial design to development strategy, regulatory decisions, and real-world treatment pathways.

The ivonescimab story shows why that connection matters: A positive Phase III result can open the door, but comparator choice, population transferability, and trial design determine how far the asset can travel.

Pharmatica: Insight. Connection. Impact.